BPS Clinical Laboratories v. Blue Cross & Blue Shield

522 N.W.2d 902, 206 Mich. App. 570
CourtMichigan Court of Appeals
DecidedSeptember 6, 1994
DocketDocket 145988, 146035, 151162, 151163, 152010, 153383
StatusPublished
Cited by2 cases

This text of 522 N.W.2d 902 (BPS Clinical Laboratories v. Blue Cross & Blue Shield) is published on Counsel Stack Legal Research, covering Michigan Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
BPS Clinical Laboratories v. Blue Cross & Blue Shield, 522 N.W.2d 902, 206 Mich. App. 570 (Mich. Ct. App. 1994).

Opinions

Michael J. Kelly, J.

Plaintiffs, independent clinical laboratories and two physicians, alleged that they wrongfully were denied the opportunity to participate as panel providers in defendant’s new health care program, Premier plus. On October 9, 1991, the circuit court granted defendant’s motion for summary disposition with regard to all issues except plaintiffs’ claim under the Prudent Purchaser Act (ppa), MCL 550.51 et seq.; MSA 24.650(51) et seq., which the court found defendant had violated. The parties each appeal the court’s summary disposition decision adverse to it. Defen[574]*574dant also appeals an order of March 18, 1992, enjoining operation of Premier plus until defendant filed the criteria for participating in the program with the Insurance Commissioner and reconsidered plaintiffs’ applications, and an order of April 9, 1992, denying defendant’s motion for security pending appeal. The appeals were consolidated. We affirm the order of April 9, 1992, reverse the order of March 18, 1992, and affirm that part of the October 9, 1991, order dismissing all of plaintiffs’ claims except the ppa claim. We reverse the part of the October 9, 1991, order finding defendant in violation of the ppa and order it amended to reflect a grant of summary disposition for defendant in light of defendant’s preemption defense under the Employee Retirement Income Security Act (erisa), 29 USC 1001 et seq.

i

Defendant is a nonprofit health care corporation. It administers General Motors Corporation’s traditional option coverage program under an "administrative services only” contract, which requires General Motors to pay defendant a fee for administering the program and reimburse defendant for all covered health care charges paid by defendant on behalf of program enrollees. Defendant is not an insurer for General Motors’ employees. The Premier Prudent Laboratory Use Program (Premier plus) is a diagnostic laboratory network pilot program developed, marketed, and implemented by defendant. Employees under General Motors’ self-funded, traditional option coverage plan were the first group to enroll in the program when, in 1990 and 1991, the Corporation-Union Committee on Health Care Benefits at General Motors evaluated potential pilot programs for laboratory ser[575]*575vices and approved Premier plus. Although defendant developed Premier plus in part out of a desire to negotiate contracts with the employee health benefit plans for Ford, Chrysler, AT&T, and Ameritech and planned to use Premier plus in its own employee benefit plan, General Motors is apparently the only entity enrolled in the program at this time. The General Motors traditional option coverage program is an "employee benefit plan” for purposes of the erisa.

Before implementation of the Premier plus program, defendant paid all diagnostic laboratories according to a maximum-fee schedule. Health care providers who drew blood and sent the samples to the laboratories for analysis received a $3 blood-handling fee from defendant.

Under the Premier plus program, defendant established a panel of six provider laboratories, which agreed to discount the rate charged to defendant for services rendered. Physicians who referred blood specimens to nonpanel laboratories would not receive the $3 blood-handling fee. Non-panel laboratories themselves would be reimbursed only fifty percent of the maximum payment scheduled. In addition, the new program differentiated between standard and nonstandard laboratory procedures. Physicians who performed nonstandard procedures would be reimbursed fifty percent of the maximum fee scheduled. The range of services eligible for reimbursement under the program, whether in whole or in part, remained the same.

n

Plaintiffs are health care providers excluded from full reimbursement under Premier plus. On March 27, 1991, plaintiffs sued defendant, alleging [576]*576that Premier plus violated the Nonprofit Health Care Corporation Reform Act (Act 350), MCL 550.1101 et seq.; MSA 24.660(101) et seq., and resulted in a tortious interference in the established business relationship between plaintiffs and referring physicians. Plaintiff doctors also alleged that Premier plus constituted a breach of contract with defendant.

Plaintiff American Health Resources, Inc., filed a complaint for mandamus on April 25, 1991, requesting that defendant be ordered to comply with the ppa by allowing it to apply for membership as a panel provider in Premier plus. The complaint also alleged an unlawful attempt to establish a monopoly in violation of the Antitrust Reform Act, MCL 445.771 et seq.; MSA 28.70(1) et seq. The two cases were consolidated and assigned to the same circuit judge.

Defendant removed the cases to the federal district court, arguing that plaintiffs’ claims were subject to complete preemption under federal law by the erisa. The federal court, on the basis of the face of the complaints, found that it did not have subject-matter jurisdiction under the erisa and remanded the case to the circuit court on August 7, 1991. It expressly left open the question whether the erisa preempted plaintiffs’ state law claims.

On August 27, 1991, defendant moved for summary disposition. The circuit court granted the motion on October 9, 1991, except with regard to plaintiffs’ claim under the ppa, which the court found defendant had violated. With regard to that claim, the court issued a final order requiring defendant to accept applications from plaintiffs for participation in Premier plus. In addition, the court permitted plaintiffs to reinstate their claim for money damages if defendant refused to accept [577]*577their applications. It also continued a temporary restraining order issued on August 14, 1991, which permitted plaintiffs to be treated as panel providers in Premier plus.

On October 31, 1991, defendant rejected all of plaintiffs’ applications. On November 13, 1991, the circuit court continued the temporary restraining order with regard to BPS Clinical Laboratories, Michigan Clinical Laboratory, and Universal Standard Medical Laboratories, Inc.

On December 20, 1991, the circuit court found that defendant had continued to violate the ppa and also had violated the October 9, 1991, order. It issued an additional final order requiring defendant to submit its standards for panel membership to the Insurance Bureau within sixty days and added that it would enjoin operation of Premier plus if defendant did not comply. The court once again extended the temporary restraining order.

Subsequently, defendant moved for relief from this order and to stay any further proceedings, arguing that the order was void as an improper modification of the October 9, 1991, order and that, nonetheless, it had complied with the December 20, 1991, order. The court denied the motion on March 18, 1992, finding that defendant had not filed its standards with the Insurance Commissioner before reviewing plaintiffs’ applications. The court enjoined operation of Premier plus until defendant filed its standards and considered plaintiffs’ applications in light of those standards.

Defendant moved for security to protect its interests pending appeal. The circuit court denied the motion in an order dated April 9, 1992.

Concurrent with the circuit court proceedings, the Insurance Commissioner also reviewed allegations that defendant had not complied with statutory regulations in implementing Premier plus.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

BPS Clinical Laboratories v. Blue Cross & Blue Shield
552 N.W.2d 919 (Michigan Court of Appeals, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
522 N.W.2d 902, 206 Mich. App. 570, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bps-clinical-laboratories-v-blue-cross-blue-shield-michctapp-1994.